Key Points
- Medpace CEO August Troendle sold 23,178 shares on Dec. 1 at an average of $593.25 for proceeds of $13.75M, reducing his stake by 3.43% to 652,550 shares; the sale was disclosed in an SEC filing.
- Quarterly results beat expectations: Medpace reported $3.86 EPS vs. $3.50 expected and revenue of $659.9M (up 23.7% year-over-year), and set FY2025 guidance of $14.600–14.860 EPS.
- Heavy institutional ownership but mixed analyst views: Institutions own 77.98% of the stock with large inflows from firms like AQR and Arrowstreet, while analyst consensus is a "Hold" with a $487.18 price target amid varied ratings.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 23,178 shares of Medpace stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $593.25, for a total transaction of $13,750,348.50. Following the transaction, the chief executive officer directly owned 652,550 shares in the company, valued at approximately $387,125,287.50. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Medpace Stock Down 1.2%
Medpace stock opened at $576.49 on Thursday. The firm has a market cap of $16.24 billion, a P/E ratio of 40.31, a P/E/G ratio of 2.21 and a beta of 1.43. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26. The business has a fifty day moving average of $565.74 and a two-hundred day moving average of $450.35.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter in the previous year, the firm earned $3.01 earnings per share. The firm's quarterly revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. AQR Capital Management LLC grew its position in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock valued at $518,170,000 after acquiring an additional 404,226 shares during the period. Norges Bank purchased a new position in Medpace during the second quarter worth approximately $66,597,000. Arrowstreet Capital Limited Partnership grew its holdings in Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company's stock valued at $161,523,000 after purchasing an additional 211,411 shares during the period. Clarkston Capital Partners LLC purchased a new stake in shares of Medpace in the second quarter valued at approximately $40,569,000. Finally, Mawer Investment Management Ltd. raised its stake in shares of Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company's stock worth $256,559,000 after buying an additional 121,213 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on the company. Robert W. Baird set a $613.00 price target on Medpace in a research report on Friday, October 24th. Barclays upped their target price on Medpace from $425.00 to $485.00 and gave the company an "underweight" rating in a research report on Friday, October 24th. Mizuho raised their price target on Medpace from $575.00 to $655.00 and gave the stock an "outperform" rating in a report on Friday, October 24th. Weiss Ratings restated a "buy (b)" rating on shares of Medpace in a research note on Friday, October 31st. Finally, Zacks Research raised shares of Medpace from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $487.18.
Get Our Latest Analysis on MEDP
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
